TRAW Traws Pharma, Inc.

NASDAQ
$0.23

Traws Pharma, Inc. (TRAW) is expected to report earnings on February 15, 2027, after the market close. The consensus earnings estimate is a loss of $0.19 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -12.0% since its last earnings release on November 16, 2026.

Traws Pharma Beat Consensus Estimates
Monday, November 16, 2026 · 4:35 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 15
Monday · 4:30 PM ET
Earnings Whisper
-
vs ($0.19)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $0.23

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Traws Pharma, Inc.

Traws Pharma Inc. is involved in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Traws Pharma Inc., formerly known as Onconova Therapeutics Inc., is based in NEWTOWN, Pa.

Sector

Healthcare

Industry

Drug Manufacturers/Other

Charts powered in part by Lightweight Charts™ by TradingView.